4H11-28z + fIL-12

4H11-28z + fIL-12 is a combination cell therapy comprising autologous T cells engineered to express a chimeric antigen receptor (CAR) targeting the MUC16ecto domain (via the 4H11-28z construct) and to secrete a flexible interleukin-12 (fIL-12) cytokine. The CAR construct enables selective recognition and targeted cytotoxicity against MUC16-expressing tumor cells, notably ovarian and pancreatic cancers. The secretion of fIL-12 enhances T cell activation, proliferation, and effector function, including increased production of interferon-gamma (IFN-γ) and IL-12 itself, augmenting anti-tumor immunity. This therapy is being evaluated in phase I clinical trials primarily for MUC16-positive recurrent ovarian cancer. The modified T cells also often express a truncated EGFR (EGFRt) to allow for targeted depletion of the CAR T cells if necessary. Development is primarily led by Memorial Sloan Kettering Cancer Center.

Other names

IL-12 secreting MUC-16(ecto) directed chimeric antigen receptorsIL-12 secreting MUC16ecto-targeted CAR T cellsIL12 secreting MUC16ecto-targeted CAR T cellsIL 12 secreting MUC16ecto-targeted CAR T cells